Cargando…

Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study

Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three intereste...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei-Ting, Lin, Chin, Tsai, Min-Chien, Cheng, Cheng-Chung, Chen, Sy-Jou, Liou, Jun-Ting, Lin, Wei-Shiang, Cheng, Shu-Meng, Lin, Chin-Sheng, Tsao, Tien-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696728/
https://www.ncbi.nlm.nih.gov/pubmed/33202854
http://dx.doi.org/10.3390/biomedicines8110499
_version_ 1783615470417477632
author Liu, Wei-Ting
Lin, Chin
Tsai, Min-Chien
Cheng, Cheng-Chung
Chen, Sy-Jou
Liou, Jun-Ting
Lin, Wei-Shiang
Cheng, Shu-Meng
Lin, Chin-Sheng
Tsao, Tien-Ping
author_facet Liu, Wei-Ting
Lin, Chin
Tsai, Min-Chien
Cheng, Cheng-Chung
Chen, Sy-Jou
Liou, Jun-Ting
Lin, Wei-Shiang
Cheng, Shu-Meng
Lin, Chin-Sheng
Tsao, Tien-Ping
author_sort Liu, Wei-Ting
collection PubMed
description Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three interested statins in a tertiary hospital between 2006 and 2018. Among them, 8337 non-diabetic patients taking moderate-intensity statins (2 mg/day pitavastatin, 10 mg/day atorvastatin, and 10 mg/day rosuvastatin) were included. The pitavastatin group had a higher probability of being NODM-free than the atorvastatin and rosuvastatin groups during the 4-year follow-up (log-rank test: p = 0.038). A subgroup analysis revealed that rosuvastatin had a significantly higher risk of NODM than pitavastatin among patients with coronary artery disease (CAD) (adjusted HR [aHR], 1.47, 95% confidence interval [CI], 1.05–2.05, p = 0.025), hypertension (aHR, 1.26, 95% CI, 1.00–1.59, p = 0.047), or chronic obstructive pulmonary disease (COPD) (aHR, 1.74, 95% CI, 1.02–2.94, p = 0.04). We concluded that compared with rosuvastatin, reduced diabetogenic effects of pitavastatin were observed among patients treated with moderate-intensity statin who had hypertension, COPD, or CAD. Additional studies are required to prove the effects of different statins on the risk of NODM.
format Online
Article
Text
id pubmed-7696728
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76967282020-11-29 Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study Liu, Wei-Ting Lin, Chin Tsai, Min-Chien Cheng, Cheng-Chung Chen, Sy-Jou Liou, Jun-Ting Lin, Wei-Shiang Cheng, Shu-Meng Lin, Chin-Sheng Tsao, Tien-Ping Biomedicines Article Statins constitute the mainstay treatment for atherosclerotic cardiovascular disease, which is associated with the risk of new-onset diabetes mellitus (NODM). However, the effects of individual statins on the risk of NODM remain unclear. We recruited 48,941 patients taking one of the three interested statins in a tertiary hospital between 2006 and 2018. Among them, 8337 non-diabetic patients taking moderate-intensity statins (2 mg/day pitavastatin, 10 mg/day atorvastatin, and 10 mg/day rosuvastatin) were included. The pitavastatin group had a higher probability of being NODM-free than the atorvastatin and rosuvastatin groups during the 4-year follow-up (log-rank test: p = 0.038). A subgroup analysis revealed that rosuvastatin had a significantly higher risk of NODM than pitavastatin among patients with coronary artery disease (CAD) (adjusted HR [aHR], 1.47, 95% confidence interval [CI], 1.05–2.05, p = 0.025), hypertension (aHR, 1.26, 95% CI, 1.00–1.59, p = 0.047), or chronic obstructive pulmonary disease (COPD) (aHR, 1.74, 95% CI, 1.02–2.94, p = 0.04). We concluded that compared with rosuvastatin, reduced diabetogenic effects of pitavastatin were observed among patients treated with moderate-intensity statin who had hypertension, COPD, or CAD. Additional studies are required to prove the effects of different statins on the risk of NODM. MDPI 2020-11-13 /pmc/articles/PMC7696728/ /pubmed/33202854 http://dx.doi.org/10.3390/biomedicines8110499 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Wei-Ting
Lin, Chin
Tsai, Min-Chien
Cheng, Cheng-Chung
Chen, Sy-Jou
Liou, Jun-Ting
Lin, Wei-Shiang
Cheng, Shu-Meng
Lin, Chin-Sheng
Tsao, Tien-Ping
Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title_full Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title_fullStr Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title_full_unstemmed Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title_short Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on the Risk of New-Onset Diabetes Mellitus: A Single-Center Cohort Study
title_sort effects of pitavastatin, atorvastatin, and rosuvastatin on the risk of new-onset diabetes mellitus: a single-center cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696728/
https://www.ncbi.nlm.nih.gov/pubmed/33202854
http://dx.doi.org/10.3390/biomedicines8110499
work_keys_str_mv AT liuweiting effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT linchin effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT tsaiminchien effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT chengchengchung effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT chensyjou effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT lioujunting effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT linweishiang effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT chengshumeng effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT linchinsheng effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy
AT tsaotienping effectsofpitavastatinatorvastatinandrosuvastatinontheriskofnewonsetdiabetesmellitusasinglecentercohortstudy